kabutan

JCR Pharmaceuticals Co.,Ltd.(4552) Summary

4552
TSE Prime
JCR Pharmaceuticals Co.,Ltd.
729
JPY
+23
(+3.26%)
Dec 5, 12:47 pm JST
4.69
USD
Dec 4, 10:47 pm EST
Result
PTS
outside of trading hours
729
Dec 5, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
29.6
PBR
1.85
Yield
2.74%
Margin Trading Ratio
17.02
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
704 JPY 4.53 USD
Previous Close Dec 4
706 JPY 4.54 USD
High Dec 5, 9:34 am
742 JPY 4.78 USD
Low Dec 5, 9:00 am
702 JPY 4.52 USD
Volume
832,100
Trading Value
0.60B JPY 3.89M USD
VWAP
726.08 JPY 4.68 USD
Minimum Trading Value
72,900 JPY 469 USD
Market Cap
0.09T JPY 0.61B USD
Number of Trades
1,064
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,239
1-Year High Jun 2, 2025
15,312
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 289,600 2,399,000 8.28
Nov 21, 2025 171,000 2,481,200 14.51
Nov 14, 2025 174,400 2,839,800 16.28
Nov 7, 2025 168,500 3,331,000 19.77
Oct 31, 2025 284,800 3,498,000 12.28
Company Profile
JCR Pharmaceuticals Co., Ltd. specializes in growth hormone products and focuses on biosimilars. The company collaborates with PeptiDream in creating carrier peptides.
Sector
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. develops, manufactures, and sells medical pharmaceuticals, regenerative medicine-related products, and pharmaceutical raw materials, primarily targeting rare disease areas. Through its group companies, the company engages in a wide range of activities including purchasing, facility management, market research, clinical trial supervision, pharmaceutical development, and intellectual property management. Internationally, JCR has subsidiaries in Brazil, Europe, and the United States, which handle clinical operations, regulatory affairs, and development tasks. The company also manages the distribution of pharmaceuticals and their raw materials, as well as contract manufacturing. JCR has affiliated companies involved in research and development, manufacturing, and sales in the regenerative medicine field, and has a proven track record in biosimilars.